Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
IN INCY INCYTE CORP FY ended Feb 03, 2026 | $124.37 | $24.85B | $22.95B | $5.14B | $1.76B | $1.29B | 19.40x | 4.83x | 13.04x |
BP BPMC Blueprint Medicines Corp FY ended Feb 11, 2025 | — | — | — | $508.82M | $23.69M | -$67.09M | — | — | — |
AD ADPT Adaptive Biotechnologies Corp FY ended Feb 20, 2026 | $25.19 | $4.02B | $4.19B | $276.98M | -$29.89M | -$59.50M | -64.59x | 14.51x | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 14.60x | 2/4 | -$4.41B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSExcluded | Equity Multiple | 8.57x | 3/4 | $0.00 | — | Target fundamentals do not produce a usable positive equity value. |
Price / Earnings PEExcluded | Equity Multiple | -4.93x | 3/4 | $1.55B | $16.44 | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
IN INCY INCYTE CORP FY ended Feb 03, 2026 | $124.37 | $24.85B | $22.95B | $5.14B | $1.76B | $1.29B | 19.40x | 4.83x | 13.04x |
BP BPMC Blueprint Medicines Corp FY ended Feb 11, 2025 | — | — | — | $508.82M | $23.69M | -$67.09M | — | — | — |
AD ADPT Adaptive Biotechnologies Corp FY ended Feb 20, 2026 | $25.19 | $4.02B | $4.19B | $276.98M | -$29.89M | -$59.50M | -64.59x | 14.51x | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 14.60x | 2/4 | -$4.41B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSExcluded | Equity Multiple | 8.57x | 3/4 | $0.00 | — | Target fundamentals do not produce a usable positive equity value. |
Price / Earnings PEExcluded | Equity Multiple | -4.93x | 3/4 | $1.55B | $16.44 | Peer averages are not economically meaningful for this method. |
